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between outbreak or epidemic.
But when you see something
that’s involving so many people in
so many states, I think it’s
probably helpful to think of it as
an expanding, emerging infectious
disease epidemic.’ In what sense
this was ‘helpful,’ she didn’t say.
Not all broadcasts were so
informative. CNN held true to its
commitment to fill airtime
regardless of whether it had
factual information to contribute.
The host of CNN Saturday
Morning News asked network
medical correspondent Elizabeth
Cohen whether a person once
infected with West Nile would
become immune. Her reply:
‘Unfortunately I’m unable to
answer that question. I do not
know, because there has been —
this is — even though this has
scared the everything out of all of
us, this is a relatively new virus, it
has only been around since 1999.’
The host chimed in helpfully,
‘Elizabeth, I did actually read a
little bit earlier that in a case of —
if you have already been bitten —
or if you have already been
exposed to West Nile through a
mosquito bite, that that does
make you immune, and you’re not
likely to get it again. And that’s
just something I read through
from the CDC reports during the
week.’
Later in this unrehearsed (and
obviously ill-prepared) segment,
CNN went on to inform its viewers
that West Nile differs from malaria
in part because there is a vaccine
for malaria. Oh really?
In contrast to that hand-
wringing, the New York Times
treated the story with sang froid
(perhaps to confuse the
mosquitoes?). One article led off,
‘As West Nile fever spreads
through the country, it is giving
scientists a rare picture of how a
virus carves a new ecological
niche in a hemisphere where it
has never been seen.’ An opinion
piece by John Barry at Tulane and
Xavier universities noted that
West Nile is considerably less
deadly than St. Louis encephalitis,
which has been causing illnesses
and deaths in the United States
since 1933, but has never enjoyed
the notoriety of its African kin.
‘Despite the publicity about the 
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disease, there is no indication that
it will erupt into an epidemic,’ he
wrote the day before CDC director
Gerberding declared otherwise on
CBS.
The Ottawa Sun also noted the
disproportionate attention being
paid to a disease that kills far fewer
people than lightning bolts. Ontario,
it noted, is gearing up to spend $9
million to fight West Nile Virus.
‘That’s half the annual budget for
tobacco control. Tobacco kills
12,000 a year in Ontario; again, the
running total for West Nile
casualties in the province is zero.’
Most news articles concluded
that West Nile is yet another fact
of life Americans will have to cope
with. It will be an uphill battle for
this disease to displace some of
the more popular fears. Ann
Brown, head of a consumer group
called Safer America for Everyone,
said she’s worried that the West
Nile panic will lead to overuse of
the pesticide DEET. ‘Children are
at the lowest risk for West Nile
virus,’ Brown told USA Today.
‘You don’t want to give them
another risk, which is to put too
much chemical on them.’
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Doubts about the European
Union’s plans to regulate funding
of stem cell research continue to
rumble and may still upset plans
for the start of the next funding
phase of the EU’s biggest research
programme. The EU’s Framework
6 (FW6) is set to launch later this
year. The 17.5 billion Euro budget
for the programme, which will run
for the next four years, funds
collaborative research between
scientists in member countries and
some associated states, and
included a significant share for
biomedical research.
The issue of funding stem-cell
research as part of the package
has proved thorny with many
member states opposed to any
research on embryo-derived stem
cells, particularly amongst
predominantly southern Catholic
states and Germany. In contrast,
regulations to work on embryo-
derived stem cells have already
been established in the UK.
Spain, which held the EU
presidency earlier this year, made
great efforts to resolve the
conflicting views by advocating
the shift of EU funds for such work
to adult-derived stem cells rather
than embryo-derived cells. It was
thought they had managed to win
agreement so that the FW6
programme could go ahead on
schedule.
But Denmark, now holding the
EU presidency, has raised fresh
concerns about the EU’s ability to
monitor the ethical aspects of
such research.
And a tough stance for funding
embryo stem cell research would
cause some problems for countries
like the UK. Although EU research
policy would not affect UK funded
work, it could make it more difficult
for UK researchers to collaborate
with their European colleagues if
EU funds were involved.
The European Commission in
Brussels will now be working
overtime to satisfy any Danish
concerns. Particularly as the
research commissioner, Philippe
Busquin, has made great play of
the timetable for implementation.
‘For the first time in the history of
Community research, we have not
left adoption of the Framework
Programme to the very last
moment — we have the time to
guarantee that it will be launched
and implemented under the very
best conditions,’ he said.
All those eager to bid for the
first tranche of funding under the
new programme will be as keen as
the administrators in Brussels that
all these issues are resolved very
soon.
Launch of the European Union’s
new Framework research
programme still has one worry.
Nigel Williams reports. 
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